Abstract | BACKGROUND: METHODS AND RESULTS: We retrospectively analyzed 42 consecutive PAH patients who underwent IVI epoprostenol in Keio University Hospital from 2001 to 2013. The study group comprised 30 women with a mean age of 34.3 ± 1.9 years. The etiology of PAH was idiopathic or heritable PAH (I/ HPAH) in 38 cases, PAH associated with connective tissue disease in 3, and Eissenmenger's syndrome in the remaining case. We divided the patients into rapid- and slow-initiation therapy groups according to the cumulative epoprostenol dose administered during the first 180 days, and compared the hemodynamic changes between the groups. The median cumulative doses were 6142 ± 165 μg/kg and 3998 ± 132 μg/kg epoprostenol, respectively. While there were no significant differences in mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), or cardiac index (CI) between the groups before the IVI epoprostenol therapy, the rapid-initiation therapy group achieved significant improvements in these hemodynamic data compared with the slow-initiation therapy group (P < 0.005) at the follow-up right-heart catheterization (RHC). CONCLUSION: Rapid initiation of IVI epoprostenol therapy achieved the optimal hemodynamic improvements in patients with severe PAH.
|
Authors | Mai Kimura, Yuichi Tamura, Makoto Takei, Tsunehisa Yamamoto, Tomohiko Ono, Masataka Kuwana, Keiichi Fukuda, Toru Satoh |
Journal | PloS one
(PLoS One)
Vol. 10
Issue 4
Pg. e0121894
( 2015)
ISSN: 1932-6203 [Electronic] United States |
PMID | 25844932
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antihypertensive Agents
- Epoprostenol
|
Topics |
- Adult
- Antihypertensive Agents
(administration & dosage, pharmacology)
- Cardiac Catheterization
(methods)
- Epoprostenol
(administration & dosage, pharmacology)
- Familial Primary Pulmonary Hypertension
(drug therapy, physiopathology)
- Female
- Hemodynamics
(drug effects)
- Humans
- Infusions, Intravenous
- Male
- Retrospective Studies
- Treatment Outcome
|